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OBJECTIVES A simple risk score on admission to estimate the likelihood of in-hospital coronary artery
bypass graft surgery (CABG) might be useful in selecting patients for early clopidogrel
therapy.
BACKGROUND Routine early use of clopidogrel in patients with unstable angina (UA) and non–ST-segment
elevation myocardial infarction (NSTEMI) is associated with increased risk of bleeding in
patients who undergo early CABG.
METHODS The test cohort utilized to derive the score was the 2,220 patients with UA/NSTEMI
enrolled in the Treat Angina with Aggrastat and Determine Cost of Therapy with an Invasive
or Conservative Strategy–Thrombolysis in Myocardial Infarction-18 (TACTICS–TIMI-18)
trial. Patients who underwent CABG after randomization during index hospitalization were
identified and were compared with patients who did not undergo in-hospital CABG.
RESULTS Overall, 362 patients (16.3%) underwent CABG during the index hospitalization. Patients
with a history of prior CABG (n  484) were significantly less likely to undergo in-hospital
CABG (odds ratio [OR], 0.34). Five additional variables independently associated with
CABG were identified: elevated troponin (OR, 3.9), prior stable angina (OR, 1.8),
ST-segment deviation 0.5 mm (OR, 1.7), male gender (OR, 1.6), and history of peripheral
arterial disease (OR, 1.6). A CABG risk score was generated by assigning numerical values
to each of the variables based upon these odds ratios. Coronary artery bypass surgery rates
increased significantly with increasing risk scores (6.2% for a risk score 3.0, 21.9% for 3 to
5, and 54.6% for 5.0). The association of the risk score with CABG was highly significant
(p  0.0001, c-statistic 0.72). The association remained significant in the validation cohorts
from TIMI-11B trial and TIMI-III registry.
CONCLUSIONS Among patients with UA/NSTEMI, a novel risk score based on admission clinical variables
can be used to estimate the likelihood of CABG. These data may assist in the identification
of patients who might derive optimal benefit from early initiation of clopidogrel
therapy. (J Am Coll Cardiol 2004;44:799–803) © 2004 by the American College of
Cardiology Foundationc
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Nombination anti-platelet therapy with aspirin and clo-
idogrel improves outcomes in patients with unstable
ngina (UA) and non–ST-segment elevation myocardial
nfarction (NSTEMI) (1). The current American College
f Cardiology/American Heart Association guidelines
ecommend addition of clopidogrel to aspirin in patients
ith UA/NSTEMI upon admission to the hospital (2).
hese beneficial effects are mediated by the enhanced
latelet inhibition that follows administration of combi-
ation therapy, which also results in an increase in the
isk of major bleeding in patients undergoing early
From the *Oklahoma University Health Sciences Center, Oklahoma City, Okla-
oma; †Harvard Medical School and the Department of Medicine, Brigham &
omen’s Hospital, Boston, Massachusetts; and ‡Merck & Co., West Point,
ennsylvania. The TACTICS–TIMI-18 trial was funded by Merck & Co.
Manuscript received January 19, 2004; revised manuscript received March 24,004, accepted March 29, 2004.oronary artery bypass graft surgery (CABG) within five
ays of administration of clopidogrel (1,3,4). Data from
everal recent trials of UA/NSTEMI indicate that 8% to
5% of patients undergo CABG after coronary angiog-
aphy (1,5–7). Withholding clopidogrel for at least five
ays before CABG reduces the risk of perioperative
leeding (1), but may lead to prolonged hospitalization.
urther, a policy of withholding clopidogrel until cardiac
atheterization may reduce any benefit of pretreatment
ith clopidogrel in the reduction of adverse cardiac
utcomes in the 50% to 60% of UA/NSTEMI patients
ho undergo percutaneous coronary intervention (PCI)
8). An ideal strategy would be to pretreat patients who
ill require PCI or continued medical therapy, and
ithhold clopidogrel in patients with high likelihood of
equiring early CABG. Thus, in patients with UA/
STEMI, ability to estimate the likelihood of in-
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CABG Risk Score in UA/NSTEMI August 18, 2004:799–803ospital CABG upon admission using clinical parameters
hat are readily available on presentation may be useful.
he main objective of this study was to develop and test
simple clinical risk score based on admission clinical
ariables to estimate the likelihood of in-hospital CABG
n patients with UA/NSTEMI.
ETHODS
he study population for design of the CABG risk score
as derived from TACTICS TIMI 18 trial. The details of
reat Angina with Aggrastat and Determine Cost of
herapy with an Invasive or Conservative Strategy–
hrombolysis in Myocardial Infarction-18 (TACTICS–
IMI-18) trial have been previously published (7). A total
f 2,220 patients with UA/NSTEMI were randomly as-
igned to an early invasive strategy that included routine
ardiac catheterization within 4 to 48 h and revasculariza-
ion as appropriate, or to a conservative strategy in which
ardiac catheterization was performed only if the patient
ad objective evidence of recurrent ischemia or an abnormal
tress test. All patients received aspirin, heparin, and tiro-
ban. The primary end point was a composite of death,
on-fatal reinfarction, and rehospitalization for acute coro-
ary syndromes at six months. For the purpose of this study,
atients from the total TACTICS–TIMI-18 population
ho underwent CABG after randomization during index
ospitalization were identified and were compared with
atients who did not undergo in-hospital CABG.
tatistical analysis. Clinical characteristics of patients who
nderwent CABG during the index hospitalization were
ompared with patients who did not undergo CABG.
nitial univariate comparisons of the baseline clinical vari-
bles were performed. Variables that achieved a significance
evel of p  0.20 were then selected for testing in a
ultivariate backward step-wise logistic regression model.
p value of 0.05 was required for retention in the final
odel. A CABG risk score was generated by assigning
umerical values for each variable independently associated
Abbreviations and Acronyms
CABG  coronary artery bypass graft
surgery
IQ  inter-quartile
NSTEMI  non–ST-segment elevation
myocardial infarction
OR  odds ratio
PAD  peripheral arterial disease
PCI  percutaneous coronary
intervention
TACTICS–TIMI-18  Treat Angina with Aggrastat
and Determine Cost of Therapy
with an Invasive or Conservative
Strategy–Thrombolysis In
Myocardial Infarction-18
UA  unstable anginaith CABG. A negative value was assigned if the variable eas significantly associated with reduced likelihood of
ABG. The final score was constructed by simple arith-
etic sum of numerical values assigned to each of the
ariables present. Risk score categories were collapsed (e.g.,
2, 1, and 0) when the prevalence of a given score was
1%. The c-statistic, or area under the receiver operator
haracteristic curve, was used to assess the discriminatory
apacity of the risk score. Test for trend across ordered
roups was performed for the risk score groups (Stata
ersion 7.0, Stata Corp., College Station, Texas).
alidation of the risk score. The risk score was validated
n two separate cohorts of patients with UA/NSTEMI
nrolled in the TIMI-11B trial and TIMI-III registry, using
he risk score model in the TACTICS–TIMI-18 trial. The
esign and results of TIMI-11B trial and TIMI-III registry
ave been reported (9–11). The TIMI-11B trial evaluated
,910 patients with UA/NSTEMI randomly assigned to
ither unfractionated heparin or enoxaparin. Further in-
ospital management of the patients, including decisions on
evascularization, was left to the discretion of the treating
hysician (10). The TIMI-III registry was a prospective,
bservational study of a wide variety of patients with
A/NSTEMI correlating clinical characteristics to out-
omes. A total of 3,318 patients were prospectively followed
or one year; TIMI-III registry did not mandate strict
nclusion or exclusion criteria other than admission diagno-
is of UA/NSTEMI. In addition, the management of
atients was left to the discretion of the treating physician.
hus, the study provided an insight into the “real world”
anagement of patients with UA/NSTEMI (11). In each
f these validation cohorts, the ability of the risk score to
stimate the need for CABG was evaluated.
ESULTS
ata from 2,220 patients with UA/NSTEMI in the
ACTICS–TIMI-18 trial were utilized as the derivation
ohort. Of these, 362 patients (16.3%) underwent CABG
uring the index hospitalization. Overall, 22% of the pa-
ients randomized to the invasive arm and 15% of the
atients randomized to the conservative arm underwent
n-hospital CABG. The median time from randomization
o in-hospital CABG in the overall TACTICS–TIMI-18
opulation was 3.8 days (inter-quartile [IQ] range 2.5, 6.0).
n the invasive arm, it was 3.4 days (IQ range 1.9, 4.9), and
n the conservative arm it was 5 days (IQ range 3.7, 7.9).
The baseline clinical characteristics of the two popula-
ions are shown in Table 1. Patients who underwent CABG
ere more likely to be male and were older. They were
ignificantly less likely to have had prior PCI or CABG.
hey had a higher prevalence of diabetes mellitus, history of
rior angina, prior MI, and a history of peripheral arterial
isease (PAD). They were also more likely to have ST-
egment deviation (ST-segment elevation or depression
0.5 mm) on their admission electrocardiogram as well aslevated troponin.
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August 18, 2004:799–803 CABG Risk Score in UA/NSTEMIOf the variables evaluated, six remained statistically
ignificant in the multivariate analysis. Patients with history
f prior CABG (n  484) were significantly less likely to
ndergo repeat CABG (odds ratio [OR] 0.35, p  0.0001),
nd only 7.4% of these patients eventually underwent repeat
ABG. The other variables independently associated with
n-hospital CABG (Table 2) were elevated troponin (OR
.9, p  0.0001), history of prior angina (OR 1.8, p 
.001), ST-segment deviation on the initial electrocardio-
ram (OR 1.7, p  0.0001), history of PAD (OR 1.6, p 
.038), and male gender (OR 1.6, p  0.001) (c-statistic
.72 for the full model, p  0.0001). Because an elevated
roponin was most strongly associated with the need for
ABG, a score of 3 was assigned for this variable. A score
f 2 was assigned for history of prior CABG. The other
our variables were each assigned a score of 1. The overall
ABG risk score was calculated by the arithmetic sum of
ndividual scores in the test cohort.
able 1. Comparison of Baseline Clinical Characteristics
creened as Candidate Variables for the Design of the CABG
isk-Score in TACTICS–TIMI-18 Trial
Characteristics
No CABG
(n  1857)
CABG
(n  362) p Value
ean age (yrs) 61  12 63  10 0.004
ales (%) 64 74 0.001
aucasian (%) 77 80 0.3
ypertension (%) 66 67 0.6
M (%) 27 33 0.02
yperlipidemia (%) 60 63 0.3
urrent smoker (%) 28 27 0.7
amily history of CAD (%) 44 41 0.3
rior MI (%) 40 32 0.004
rior PTCA (%) 29 19 0.0001
rior CABG (%) 24 10 0.0001
istory of angina (%) 12 17 0.02
HF (%) 7 7 0.9
rior aspirin (%) 66 67 0.9
istory of CVA (%) 5.8 4.4 0.3
istory of PAD (%) 7.1 10.0 0.08
T-segment deviation
 0.5 mm
36 52 0.0001
ositive troponin (%) 55 84 0.0001
ABG coronary artery bypass graft surgery; CAD coronary artery disease; CHF
congestive heart failure; CVA cerebrovascular accident; DM diabetes mellitus;
I  myocardial infarction; PAD  peripheral arterial disease; PTCA  percuta-
eous transluminal coronary angioplasty.
able 2. Variables Independently Associated With CABG in
ultivariate Analysis
Variables
Odds
Ratio 95% CI p Value
Risk
Score
istory of CABG 0.35 0.2–0.5 0.0001 2
) Troponin 3.9 2.7–5.5 0.0001 3
rior angina 1.8 1.3–2.6 0.001 1
T-segment deviation
 0.5 mm
1.7 1.3–2.2 0.0001 1
istory of PAD 1.6 1.1–2.6 0.038 1
ale gender 1.6 1.2–2.2 0.001 1
ABG  coronary artery bypass graft surgery; CI  confidence interval; PAD 
eripheral arterial disease. The distribution of the CABG risk scores in the
ACTICS–TIMI-18 population is shown in Figure 1.
ltogether, 42% of patients had a low risk score of 3.0,
5% had intermediate risk scores of 3 to 5, and 3% of
atients had a high risk score 5.0.
The association of CABG with increasing risk scores in
he overall TACTICS–TIMI-18 population is shown in
igure 2. There was a significant increase in the rates of
ABG with increasing risk scores. Only 6.2% of patients
ith a low risk score3.0 and 21.9% with intermediate risk
cores of 3 to 5 underwent CABG compared with the
ignificantly greater 54.6% of patients with a high risk score
5.0 (p  0.001). Similar association of CABG with
ncreasing risk scores was observed in both the invasive and
onservative arms (Fig. 3). The sensitivity, specificity, pos-
tive predictive value, and negative predictive value for high
isk scores versus low and intermediate risk scores were 55%,
5%, 10%, and 98.4%, respectively. Importantly, the asso-
iation of the risk score with rates of PCI was not as
ignificant as that of CABG. The rates of PCI seemed to be
ore evenly distributed; 25.2%, 39.7%, and 25.5% in
atients with low, intermediate, and high risk scores,
espectively.
alidation of risk score. Validation of the CABG risk
core in the TIMI-11B trial and TIMI-III registry are
hown in Figures 4 and 5. Overall, the number of patients
ho underwent CABG was much lower in the TIMI-11B
igure 1. Distribution of the coronary artery bypass surgery risk score in
he overall TACTICS–TIMI-18 patient population. Risk score: 3.0,
2%; 3 to 5, 55%; 5.0, 3%.
igure 2. Rates of in-hospital coronary artery bypass surgery (CABG) in
atients with prior CABG and low, intermediate, and high CABG risk
cores in the overall TACTICS–TIMI-18 population (n  1,828).
ssociation of the risk score with in-hospital CABG, p value for trend
0.0001; c-statistic 0.72.
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CABG Risk Score in UA/NSTEMI August 18, 2004:799–803rial than in the TACTICS–TIMI-18 trial (6.5% vs.
6.3%). However, despite the low rates of CABG, there was
similar significant association between increasing risk
cores and the need for CABG at eight days (Fig. 4). Rates
f CABG were 4.5% and 7.7% in patients with low and
ntermediate risk scores, respectively, compared with 11.5%
n patients with high risk scores (c-statistic 0.61, p 
.0001). Only 1,139 patients from TIMI-III registry qual-
fied for this analysis, as the information on variables from
he model was not routinely available and elevated creatine
inase MB was substituted for elevated troponin in the risk
core. Nonetheless, the CABG rates increased significantly
rom 8% in patients with low risk scores 3.0, to 20% in
atients with intermediate risk scores of 3 to 5, and 26% in
atients with high risk scores 5.0 (p  0.0001; c-statistic
.66) (Fig. 5).
ISCUSSION
hese results indicate that, using readily available admission
linical variables, a simple risk score can be constructed to
stimate the likelihood of CABG in a patient presenting
ith UA/NSTEMI. A CABG risk score of 5.0 was
ssociated with high likelihood of CABG (55%) during
ndex hospitalization. The association of the risk score with
igure 4. Validation of the coronary artery bypass surgery (CABG) risk
core in Thrombolysis In Myocardial Infarction (TIMI)-11b patient
opulation with unstable angina and non–ST-segment elevation myocar-
ial infarction. Association of the risk score with in-hospital CABG in
igure 3. Association of the risk score with in-hospital coronary artery
ypass surgery (CABG) in the invasive and conservative arms of
ACTICS–TIMI-18 trial. Solid bars  invasive; hatched bars 
onservative. Invasive arm (n  921) p value for trend 0.0001, c-statistic
.71; conservative arm (n  907) p value for trend 0.0001, c-statistic
.73.iIMI-11b (n  3,722), p value for trend 0.0001; c-statistic 0.61.ABG was validated in two independent UA/NSTEMI
atient populations.
In patients with UA/NSTEMI, the beneficial effects of
arly combination therapy with aspirin and clopidogrel has
learly been demonstrated at 30 days and 1 year, and were
pparent within the first 24 h after a loading dose of
lopidogrel (1). However, the irreversible platelet inhibition
hat follows this combination therapy has been associated
ith increased risk of perioperative major bleeding among
atients undergoing early CABG. Withholding clopidogrel
or at least five days (i.e., duration of effect of clopidogrel)
efore CABG reduces the risk of perioperative bleeding.
owever, such a strategy may lead to adverse events and
rolonged hospitalization due to the five to seven days
aiting period before CABG. These factors have contrib-
ted to the considerable variation in the early use of
lopidogrel in patients with UA/NSTEMI (12,13). The
bility to estimate the likelihood of CABG upon admission,
sing readily available clinical parameters, may help aid in
efining the optimal timing of clopidogrel administration.
he results of this study suggest that a prior history of
ABG or, overall, a CABG risk score3.0 (42% of patient
opulation in TACTICS–TIMI-18 trial) can help identify
atients at low risk of requiring early CABG, in whom
lopidogrel may be safely administered on admission.
Due to risks associated with repeat CABG, most patients
ith prior CABG are likely to be treated with PCI or
edical therapy unless they have universally failed grafts.
ur data bore this out; patients with prior CABG were 65%
ess likely to undergo repeat CABG. Only 7.4% of these
atients underwent repeat CABG. Given the strong nega-
ive association, these patients are, as a group, at reduced
isk for repeat CABG, and, hence, in these patients there is
ess reason to consider delaying the administration of
lopidogrel.
A CABG risk score 5.0 is associated with a high
ikelihood of requiring in-hospital CABG. Only 3% of
atients with UA/NSTEMI in TACTICS–TIMI-18 trial
ad a CABG risk score 5.0, yet a dramatic 55% of these
atients underwent CABG, compared with 6.2% and 21.9%
igure 5. Validation of the coronary artery bypass surgery (CABG) risk
core in Thrombolysis In Myocardial Infarction (TIMI)-III registry patient
opulation with unstable angina and non–ST-segment elevation myocar-
ial infarction. Association of the risk score with in-hospital CABG in
IMI-III registry (n  1,139), p value for trend 0.0001; c-statistic 0.66.n patients with low and intermediate risk scores, respec-
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August 18, 2004:799–803 CABG Risk Score in UA/NSTEMIively. The specificity and the negative predictive value of
he risk score were high, 85% and 98.4%. Thus, in patients
ith UA/NSTEMI, a low CABG risk score 3.0 is
ssociated with low likelihood of CABG, and clopidogrel
an be initiated immediately on admission. On the other
and, a high CABG risk score 5.0 is strongly associated
ith need for CABG, and one might consider withholding
lopidogrel until early angiography and definition of coro-
ary anatomy. However, the assumption that such a strategy
f withholding clopidogrel until early angiogram improves
afety with similar efficacy is speculative and needs to be
ested prospectively in future clinical trials. Patients with
ntermediate risk scores of 3 to 5 constituted 55% of
ACTICS–TIMI-18 population and had a CABG rate of
1.9%. Although the decision on clopidogrel in these
atients could be challenging, it should be individualized
sing judgment on risk versus benefit. It is likely that, with
he advent of drug-eluting stents, an increasing proportion
f these patients may be treated with multivessel PCI
nstead of CABG.
onclusions. In patients with UA/NSTEMI, a simple risk
core based on admission clinical variables estimates the
ikelihood of CABG. A risk score of3.0 is associated with
very low likelihood of CABG, and a risk score of 5.0 is
ssociated with a high likelihood of CABG during hospi-
alization. These data may help decisions on initiation of
lopidogrel upon admission with UA/NSTEMI.
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